- Home
- SLQT vs RLMD Comparison
SLQT vs RLMD Comparison
Compare SLQT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | RLMD |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.6M | 307.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLQT | RLMD |
|---|---|---|
| Price | $1.51 | $4.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.88 | ★ $5.50 |
| AVG Volume (30 Days) | 864.0K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,563,142,000.00 | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $1.33 | $0.24 |
| 52 Week High | $6.86 | $5.12 |
Technical Indicators
Market Signals| Indicator | SLQT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 56.92 |
| Support Level | $1.38 | $3.95 |
| Resistance Level | $1.50 | $4.72 |
| Average True Range (ATR) | 0.07 | 0.44 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 75.00 | 38.84 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.